DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

Recruiting

Phase 3

Obrixtamig & Standard TreatmentDAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy

Sponsor:

Boehringer Ingelheim

Code:

NCT07472517

Conditions

Small Cell Lung Cancer (SCLC)

Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

obrixtamig

atezolizumab

carboplatin

etoposide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-07-04. This information was provided to ClinicalTrials.gov by Boehringer Ingelheim on 2026-06-23.